کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10908990 | 1087820 | 2014 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p = 0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p = 0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 38, Issue 4, April 2014, Pages 475-483
Journal: Leukemia Research - Volume 38, Issue 4, April 2014, Pages 475-483
نویسندگان
Lisa Pleyer, Ulrich Germing, Wolfgang R. Sperr, Werner Linkesch, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Martin Schreder, Michael Pfeilstocker, Alois Lang, Thamer Sliwa, Dietmar Geissler, Konstantin Schlick, Gudrun Placher-Sorko,